Toolkit 5 Feb 2016

WADA cooperation risk assessment template

In the context of the cooperation in the fight against doping in sport, companies can use this template to undertake a review of project compounds (from candidate selection onward) to assess potential for risk for doping potential. This information will be reviewed internally for risk classification consisting of: A) no or negligible risk, B) possible...

Read more
Press release 4 Feb 2016

World cancer day: R&D pharmaceutical industry partnerships to enhance access to cancer care

Cancer is one of the greatest health challenges of our time, and a leading cause of death in every corner of the world. Within the next two decades it is expected we reach 22 million new cases of cancer each year, the majority of them in low-and middle-income countries (LMICs). Without the preventative measures, the...

Read more
Report 28 Jan 2016

The complex journey of a vaccine-part II

Read more
Report 28 Jan 2016

PAHO Foundation annual progress report to IFPMA

Read more
Position paper 26 Jan 2016

Mental and neurological disorders addressing a global health priority

 

Read more
Report 25 Jan 2016

Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance

Read more
Press release 18 Jan 2016

Partnership to improve prevention of women’s cancers and quality of cancer registries in LAC reaches 1 year milestone

The Women’s Cancer Initiative in the Americas works to improve the quality and effectiveness of national breast and cervical cancer programs and the quality and completeness of national cancer registries in the region. The three-year partnership has reached its 1 year milestone and today launches its annual report to detail progress made in 2015. PAHO...

Read more
Expert insight 11 Dec 2015

Jumping the Health Care Hurdles: UHC and Non-Communicable Diseases

This blog was originally posted on Devex. An estimated 400 million people do not have access to basic health care services. That’s about 1 in every 16 people who cannot visit a hospital or clinic to have their blood pressure measured, or learn how to properly care for their child with diabetes. Universal health coverage...

Read more
Video 8 Dec 2015

IFPMA 2015 interview series ‘Biodiversity, human health, and pharma’

A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What’s key is to increase the awareness of the potential impacts of the Nagoya Protocol on research and on our ability...

Read more
Statement 8 Dec 2015

IFPMA statement on climate change and health

  The driving motivation of the pharmaceutical industry is to improve human health and well-being. Climate change will challenge the global community in its efforts to tackle health concerns and inequalities across the world. It can have consequences both for people living today, especially the poorest and most vulnerable, and for future generations. It is...

Read more
Video 4 Dec 2015

2015 IFPMA pharma by numbers – Video

Have a quick look at our ‘pharma by numbers’ video illustrating the key 2015 facts & figures that range from innovation in R&D, to pharma & global health, and the pharma economic footprint. This video is based on the IFPMA yearly flagship publication http://ifpma.org

Read more
Infographic 4 Dec 2015

IFPMA 2015 pharma by numbers

Read more